News

Activation Capital Announces Plans for Development of Innovation Center – A New Life Sciences Center at Bio+Tech Park

Activation Capital, an innovation ecosystem development organization, announced plans to develop the 102,000-square foot Innovation Center in the Bio+Tech Park in Richmond, Virginia.

The 34-acre Bio+Tech Park is a commercial life sciences hub in downtown Richmond adjacent to the VCU Medical Center at Virginia Commonwealth University, and is home to over 70 companies, research institutes, and state/federal laboratories. Activation Capital recently announced Virginia Gov. Glenn Youngkin awarded Activation Capital a $15 million portion of a total $66.7 million in grant funding for life sciences projects in the Commonwealth of Virginia.

Amy J. Broderick and Kate Hosko of Cushman & Wakefield | Thalhimer, along with David Thomann of Cushman & Wakefield’s Life Science Group in Boston, MA, have been awarded the exclusive leasing representation for the Innovation Center. Planned for delivery in late 2025, the center will feature approximately 35,000+ square feet of trophy class lab and creative office space for a lead tenant. Approximately 45,000 sf will be dedicated to an incubator operated by Activation Capital and will include shared labs, private offices, and community gathering spaces.  The new building will be located at the corner of 8th Street and Jackson Street.

“As part of our strategic plan to create a thriving ecosystem, Activation Capital will build an Innovation Center that anchors downtown Richmond’s innovation hub and serves as a magnet for innovators to build and grow deep tech companies. Once complete, the Innovation Center will catalyze downtown redevelopment around wealth-creating jobs, boost entrepreneurial growth, strengthen the region’s end-to-end pharmaceutical manufacturing cluster, and act as a platform for upskilling community members with STEM programming.,” said Chandra Briggman, President and CEO of Activation Capital

“In addition to their strong commercial real estate brokerage experience and national life science expertise, Cushman & Wakefield | Thalhimer was selected due to their alignment with Activation Capital’s values of agility, collaboration, entrepreneurial thinking, future-focus, impact, and inclusion,” said Kipton Currier, Vice President of Operations at Activation Capital. “The teams selected for the Innovation Center understand our commitment to the community, our excellence in execution focus, and our dedication to creating a nationally renowned life science innovation center for the benefit of future generations.”

Learn more here.

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin